All articles
Evidence-led research on repurposed compounds and the protocols people actually ask about — cited to primary literature and reviewed for accuracy.
Severe Liver Injury Reported After Co-ingestion of Veterinary Fenbendazole and Ivermectin (2026 Case Report)
A 2026 case report in Cureus documents severe drug-induced liver injury in a 65-year-old prostate cancer patient who self-administered veterinary fenbendazole and ivermectin for three months.
Artemisinin Liposomes Suppress Breast Cancer Metastasis via TIGIT/CD155 Axis (2026 Study)
A July 2026 study in Apoptosis demonstrates that artemisinin-loaded liposomes suppress breast cancer metastasis and induce apoptosis by modulating the TIGIT/CD155 immune checkpoint axis in 4T1 cell and mouse models.
Curcumin Network Pharmacology Reveals Gastric Cancer Targets in 2026 Study
A 2026 study combines network pharmacology, molecular dynamics, and in vitro experiments to explore how curcumin targets gastric cancer pathways.
Mebendazole for Brain Tumours: Systematic Review Synthesizes 22 Studies (2026)
A 2026 systematic review evaluates mebendazole's preclinical and clinical evidence across glioblastoma, medulloblastoma, and meningioma, highlighting translational gaps.
Repurposing Monepantel in Oncology: New 2026 Mini-Review
A 2026 conceptual review highlights monepantel's emerging anticancer mechanisms, including mTOR inhibition and autophagy induction, based on preclinical evidence.
Fenbendazole
Fenbendazole for Cancer by Type: A Research Hub (2026)
A curated research hub that groups our fenbendazole summaries by tumour type — lung, breast, prostate, brain, colorectal, pancreatic and ovarian — so you can jump straight to the mechanisms, case reports, dosing and safety notes for a specific cancer.
1,9-Dimethyl Methylene Blue Shows Photodynamic Activity in Oropharyngeal Carcinoma Models
A novel methylene blue derivative, 1,9-dimethyl methylene blue, shows promise as a photosensitizer for photodynamic therapy against oropharyngeal cancer.
Curcumin Analog E145 Suppresses NF-κB to Inhibit Breast Cancer Growth and Metastasis
A synthetic curcumin analog called E145 shows potent anticancer activity by blocking NF-κB signaling in breast cancer cells and reducing lung metastasis in mice.
Curcumin Calms Breast Cancer Inflammasome Activation in Tumor-Associated Macrophages
Curcumin suppresses NLRP3 inflammasome activation in tumor-associated macrophages, reducing inflammatory signals that drive breast cancer progression.
Nitazoxanide Antiparasitic Drug Induces Ferroptosis in TNBC (Redox Reports 2026)
A 2026 preclinical study shows nitazoxanide, an FDA-approved antiparasitic drug, triggers ferroptosis in TNBC cells by disrupting iron homeostasis and degrading the beta-catenin/GPX4 axis. The findings are based on in vitro and zebrafish xenograft data only.
Curcumin Analogue B-155 Outperforms Natural Curcumin in Ovarian Cancer Preclinical Study (2026)
A 2026 preclinical study found that the synthetic curcumin analogue B-155 demonstrates significantly greater cytotoxicity than natural curcumin in SKOV3 ovarian cancer cells, with effects including G2/M cell-cycle arrest, apoptosis, and p38 MAPK binding. The study is limited to in vitro data.
Mebendazole Prevents Meningioma Invasion in 3D Patient-Derived Spheroids (2026)
In a 2026 preclinical study using patient-derived 3D spheroids, mebendazole prevented cellular invasion in 89% of meningioma samples by disrupting Rho-GTPase-mediated microtubule function. This is early laboratory evidence, not a clinical trial.
Nothing here yet.